期刊文献+

晚期非小细胞肺癌基本证型探讨 被引量:17

Exploration on Basic Syndromes of Advanced Non-small Cell Lung Cancer
原文传递
导出
摘要 目的:探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的基本中医证型。方法:纳入晚期NSCLC患者338例,收集患者的临床症状,应用因子分析方法对症状进行分类,并确定证型。结果:晚期NSCLC的基本中医证型包括气虚证、阴虚证、阳虚证、肾虚证、痰湿证、瘀血证、气滞证、热毒证。结论:上述证型基本反映了体能状态(PS)评分为0~1分的晚期NSCLC的基本中医证型。 Objective: To study the basic syndromes of advanced non-small cell lung cancer (NSCLC). Methods: The clinical symptoms of 338 patients with advanced NSCLC were collected, and the method of factor analysis was applied to classify the symptoms and determine the basic syndromes. Results: The basic syndromes of advanced NSCLC included qi deficiency syndrome, yin deficiency syndrome, yang deficiency syndrome, kidney deficiency syndrome, phlegm-dampness syndrome, blood stasis syndrome, qi stagnation syndrome and heat-toxin syndrome. Conclusion: The syndromes above-mentioned can reflect the basic syndromes of advanced NSCLC patients with PS score between 0 to 1.
出处 《上海中医药大学学报》 CAS 2012年第3期44-47,共4页 Academic Journal of Shanghai University of Traditional Chinese Medicine
基金 上海市浦东新区科技发展基金创新基金资助项目(PKJ2008-Y32)
关键词 非小细胞肺癌 晚期 证型 因子分析 中医学 Non-small cell lung cancer advanced stage syndrome factor analysis Chinese medicine
  • 相关文献

参考文献28

  • 1第三次全国死因调查主要情况[J].中国肿瘤,2008,17(5):344-345. 被引量:254
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J ]. CA Cancer J Clin, 2011,61 (2) : 69-90.
  • 3Weissman CH, Reynolds CH, Neubauer MA, et al. A phase Ⅲ ran- domized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6(2) : 358-364.
  • 4Okamoto I, Yoshioka H, Morita S, et al. Phase Ⅲ trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemo- therapy-naive patients with advanced non-small-cell lung cancer: re- suits of a west ~apan oncnlogy group study[ J]. J Clin Oncol, 2010, 28 (36) : 5240-5246.
  • 5Ramalingam S, Perry MC, La Rocca RV, et al. Comparison (~f out eomes for elderly patients treated with weekly paelitaxel in eombitm tion with carhoplatin versus the standard 3-weekly paclitaxel and ear hoplatin for advanced nonsrnall cell lung eaneer[ J]. Caneer, 2008 113(3) : 542-546.
  • 6Lee SM, Rudd R, Woll PJ, et al. Randomized double-blind place- bo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer[ J]. J Clin Oncol, 2009, 27(31 ): 5248-5254.
  • 7Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer[ J]. Cancer, 2010, 116 (21) : 5038 -5046.
  • 8Stinchcombe TE, Socinski MA. Considerations for second-line ther- apy of non-small cell lung cancer [ J]. Oncologist, 2008, 13 ( Suppl l ) : 28-36.
  • 9Pallis AG, Agelaki S, Agelidou A, et al. A randomized phase Ⅲ study of the docetaxel/carboplatin combination versus docetaxel sin- gle-agent as second line treatment for patients with advanced/meta- static non-small cell lung cancer[ J ]. BMC Cancer, 2010, (10) : 633.
  • 10William WN Jr, Kies MS, Fossella FV, et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer [ J ]. Cancer, 2010, 116 (10) : 2401-2408.

二级参考文献45

共引文献911

同被引文献222

引证文献17

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部